| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-022 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 宁波美诺华药业股份有限公司（以下简称"公司"）股票于 2026 年 3 月 24 日、3 月 25 日、3 月 26 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 根据《上海证券交易所交易规则》的相关规定，属于股票交易异常波动情形。 自 2026 年 3 月 5 日至本公告提交日，公司股票价格累计上涨 75.30%；最近 5 个交易日，公司股票涨停 4 次，积累较大交易风险。公司所属 的行业分类"C27 医药制造行业"最新滚动市盈率为 27.97 倍，公司最新滚动市 盈率为 71.75 倍，显著高于同行业上市公司水平。 1 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司对有关事项进行了自查，并书面征询 公司 ...

【国泰海通医药】美诺华公布JH389临床数据并对创新研发布局进行更新 【JH389更新】 JH389是口服GLP-1肠道靶向益生菌胶囊，以基因工程改造枯草芽孢杆菌在肠道原位递送GLP-1类似物，核心用于 减重与血糖管理。 相对于GLP-1药物，JH389无消化道副反应、高可及性、低成本等优势，且差异化面向不愿打针/口服用药人群。 国际商业化方面，公司已与意大利合作方达成协议，目前正开展欧洲上市所需的安全性实验研究，有望2026年获 批。 【JH389更新】 JH389是口服GLP-1肠道靶向益生菌胶囊，以基因工程改造枯草芽孢杆菌在肠道原位递送GLP-1类似物，核心用于 减重与血糖管理。 相对于GLP-1药物，JH389无消化道副反应、高可及性、低成本等优势，且差异化面向不愿打针/口服用药人群。 国际商业化方面，公司已与意大利合作方达成协议，目前正开 【国泰海通医药】美诺华公布JH389临床数据并对创新研发布局进行更新 1）临床设计：试验采用单中心、开放、自身对照设计，试验周期为8周，入组28例，脱落率为0%。 ...

执业证书编号：S0740519040001 Email：zhujq@zts.com.cn Email：liuzq04@zts.com.cn | 上市公司数 | 504 | | --- | --- | | 行业总市值(亿元) | 67,613.55 | | 行业流通市值(亿元) | 61,920.43 | 医保基金运行平稳向好、NVIDIA GTC 勾勒 AI+蓝图；波动下关 注个股α与防御板块配置机会 医药生物 证券研究报告/行业定期报告 2026 年 03 月 22 日 1、《重视涨价逻辑演绎；"十五五" AI+机遇》2026-03-15 志物检测列项》2026-03-13 评级： 增持（维持） 分析师：祝嘉琦 联系人：刘照芊 基本状况 行业-市场走势对比 重点公司基本状况 简称 股价 EPS PE 评级 （元） 2023A 2024A 2025E 2026E 2027E 2023A 2024A 2025E 2026E 2027E 药明生物 33.82 0.82 0.81 0.96 1.17 1.47 41.16 41.69 35.31 28.90 23.06 买入 三生国健 70.03 0.48 1.14 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-021 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 序 号 | 受托方 | 产品名称 | 产品 类型 | 产品 期限 | 金额 （万元） | 已履行的 审议程序 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 招商银行 | 招商银行随心存通知存款 | 通知 存款 | 2026 年 4 月 15 日到期 | 700 | 已经公司 2025 年 4 月 17 日召开的第五届董 事会第十三次会议，以 及 2025 年 5 月 8 日召 开的 2024 年年度股东 | | | | | | | | 大会审议通过 | | | 合计 | - | - | - | 700 | - | 本次使用闲置募集资金进行现金管理具体 ...

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The pharmaceutical sector is experiencing a divergence in performance, with price increase logic and structural opportunities during the earnings window being noteworthy [7][11] - The report highlights the strong performance of the medical device sector, particularly in brain-computer interface policies and price increases for gloves, which are catalyzing market activity [11] - The "14th Five-Year Plan" has been released, clarifying the direction for the medical industry and system construction, emphasizing innovation in biomedicine and the integration of AI technologies [11][12] Summary by Sections Industry Overview - The pharmaceutical industry comprises 504 listed companies with a total market value of 69,254.89 billion [2] - The circulating market value stands at 63,426.67 billion [2] Market Dynamics - The Shanghai Composite Index rose by 0.19%, while the pharmaceutical sector fell by 0.22%, ranking 13th among 31 sub-industries [11] - The report notes a mixed performance across various segments, with medical devices and biological products showing positive trends [11] Key Recommendations - The report recommends focusing on sectors likely to see price increases, such as gloves and raw materials, as well as innovative drugs and AI applications [11] - Specific companies to watch include Innovent Biologics, Mindray Medical, and others in the innovative drug and medical device sectors [8][12] Policy and Regulatory Developments - The report discusses the approval of the first invasive brain-computer interface medical device, marking a significant milestone in the industry [16] - The "14th Five-Year Plan" outlines key technological advancements and legislative support for emerging industries, including biomedicine and AI [11][13]

Investment Rating - The report maintains an "Overweight" rating for the industry [6] Core Insights - The pharmaceutical sector is experiencing volatility and differentiation, with structural opportunities arising from policy catalysts and performance windows. The Shanghai Composite Index fell by 1.07%, while the pharmaceutical sector dropped by 2.78%, ranking 17th among 31 sub-industries. Notably, the market showed a rebound after initial geopolitical concerns, driven by positive mentions of pharmaceuticals in the government work report [8][14] - The report emphasizes the importance of the upcoming Q1 earnings reports, which are expected to provide positive catalysts, particularly for companies like Ailis, which anticipates a 41% revenue increase and a 44% rise in net profit [8][14] - The government work report highlights the development of emerging industries, including biomedicine, and reiterates the focus on innovative drugs and medical devices. This marks the third consecutive year that "innovative drugs" have been included in the report, indicating a sustained commitment to this sector [8][14] Summary by Sections Market Dynamics - The pharmaceutical sector's performance is influenced by both policy changes and market conditions, with a notable decline in various sub-sectors such as medical services and traditional Chinese medicine [8][14] - The report indicates that the pharmaceutical sector's valuation is currently at 22.4 times PE based on 2026 earnings forecasts, which is a premium of 8.4% compared to the overall A-share market [23] Investment Recommendations - The report suggests focusing on three main investment lines: 1. Leading biotech and biopharma companies that are expected to benefit from improved payment environments and global competitiveness, such as Kangfang Biotech and BeiGene [8][14] 2. Upstream and CXO sectors supported by "patient capital," with companies like WuXi Biologics and Tigermed highlighted as potential beneficiaries [8][14] 3. Cutting-edge fields such as brain-computer interfaces and AI in healthcare, with specific companies recommended for investment [8][14] Company Performance - The report notes that companies in the innovative drug sector have shown strong performance, particularly those with ongoing product developments. Conversely, stocks that previously experienced significant gains are now facing corrections [29]

Investment Rating - The report maintains a "Buy" rating for several companies including WuXi Biologics, Tigermed, and others, indicating a positive outlook for the sector [3][12][17]. Core Insights - The report emphasizes the importance of focusing on Q1 performance expectations and actively seizing thematic opportunities, particularly in areas like brain-computer interfaces, surgical robots, and AI healthcare [6][15]. - The surgical robot market in China is projected to grow rapidly, with a potential market size exceeding 100 billion yuan by 2033, driven by policy support and increasing clinical demand [10][30]. - The report highlights a strategic focus on the raw material drug sector, which is expected to see a turnaround due to rising prices and the introduction of new business lines such as small nucleic acids and ADCs [7][15]. Summary by Sections Market Performance - In February 2026, the pharmaceutical sector experienced a slight decline of 0.2%, underperforming compared to the Shanghai Composite Index, which rose by 0.1% [6][11]. - The report notes that various sub-sectors within pharmaceuticals, such as traditional Chinese medicine and medical devices, showed positive performance, with increases of 1.49% and 0.93% respectively [6][15]. Surgical Robots - The surgical robot market is on track to reach a scale of 1020.19 billion yuan by 2033, with a compound annual growth rate (CAGR) of 34.3% from 2024 to 2033 [10][23]. - The report discusses the establishment of a unified pricing framework for surgical robots, which is expected to enhance procurement willingness among hospitals [30][31]. Thematic Opportunities - The report suggests focusing on thematic opportunities in brain-computer interfaces, surgical robots, and AI healthcare, particularly as catalysts are expected to materialize soon [6][15]. - Companies such as Innovent Biologics and others are highlighted as key players in the biotech and biopharma sectors, with potential for significant growth [9][16]. Raw Material Drugs - The raw material drug sector is identified as being at a turning point, with expectations of price improvements following several years of decline [7][15]. - Companies like Pro Pharma and others are recommended for their strong business fundamentals and potential for growth in this sector [7][15].

Group 1: Key Insights on Convertible Bonds - The report highlights the top ten convertible bonds for March, including companies like Meinuohua, Tai Rui Machinery, and Jiangsu Huachen, each with unique growth drivers and market positions [2][10][21]. - The overall market sentiment is positive, with expectations of a "spring rally" driven by increased investment in technology and high-end manufacturing sectors [3][55]. - The report notes that the convertible bond market is experiencing a relative valuation high, with a decrease in median prices across various parity ranges, indicating potential investment opportunities [2][55]. Group 2: Company-Specific Insights - Meinuohua is advancing its innovative pipeline, particularly the JH389 project, which is expected to enhance its market position in the pharmaceutical sector [10]. - Tai Rui Machinery is recognized as a leading manufacturer of injection molding machines, focusing on high-end markets to compete with international players [33][34]. - Jiangsu Huachen is positioned to benefit from the global shift towards renewable energy, with a strategic focus on expanding its overseas market presence [21][22]. - Youfa Group, as the largest manufacturer of welded steel pipes in China, is leveraging its competitive advantages to navigate the upcoming supply-side reforms [19][20]. - Yubang New Materials is actively developing products for the energy storage and data center markets, anticipating significant growth in these sectors [43][44]. - Ruikeda is expanding its product offerings in the electric vehicle and data center markets, capitalizing on the growing demand for high-speed connectors [48][49]. - Hongya CNC is a leader in the furniture equipment sector, providing comprehensive automation solutions to enhance production efficiency [25][26]. - Qizhong Technology specializes in advanced packaging and testing services for integrated circuits, maintaining a competitive edge in the semiconductor industry [29][30]. - The report emphasizes the importance of monitoring the evolving market dynamics and technological advancements across these sectors to identify potential investment opportunities [3][56].

Core Viewpoint - The company, Ningbo Meinuo Pharmaceutical Co., Ltd., has completed the repurchase and cancellation of part of the restricted stock incentive plan, resulting in a slight increase in the shareholding percentage of its controlling shareholder, Ningbo Meinuo Holding Group Co., Ltd., and its actual controller, Yao Chengzhi, without changing the overall control structure of the company [3][4][5]. Group 1: Share Repurchase and Cancellation - The company has repurchased and canceled 181,100 shares from the 2024 restricted stock incentive plan, confirmed by the China Securities Depository and Clearing Corporation Shanghai Branch [3][5]. - Following the cancellation, the total share capital of the company decreased from 220,631,264 shares to 220,450,164 shares [3][4]. - The shareholding percentage of the controlling shareholder increased from 25.9963% to 26.0176% due to the reduction in total share capital, although the number of shares held remained unchanged [4][5]. Group 2: Regulatory Compliance and Disclosure - The company has adhered to the relevant regulations set forth by the China Securities Regulatory Commission regarding the disclosure of equity changes when the shareholding percentage reaches 1% increments [5]. - The equity change resulting from the share repurchase does not lead to any changes in the company's controlling shareholder or actual controller, nor does it significantly impact the company's governance structure or ongoing operations [5].

Core Viewpoint - The company, Ningbo Meinuo Pharmaceutical Co., Ltd., has completed the repurchase and cancellation of shares related to its 2024 restricted stock incentive plan, resulting in a slight increase in the shareholding percentage of its controlling shareholder, Ningbo Meinuo Holdings Group Co., Ltd. [1][2] Group 1: Share Repurchase and Cancellation - The company has repurchased and canceled 181,100 shares from its 2024 restricted stock incentive plan, which has been confirmed by the China Securities Depository and Clearing Corporation Shanghai Branch [2][4] - Following the completion of the share repurchase, the total share capital of the company has decreased from 220,631,264 shares to 220,450,164 shares [1][2] Group 2: Shareholding Changes - After the share repurchase, the combined shareholding percentage of the controlling shareholder, Ningbo Meinuo Holdings Group Co., Ltd., and its actual controller, Mr. Yao Chengzhi, has increased from 25.9963% to 26.0176% without any change in the number of shares held [2][4] - This change in shareholding percentage is due to the reduction in total share capital and does not result in a change of control or significant impact on the company's governance structure [4][5]